Singapore, July 20 -- Merck, a leading science and technology company, has opened a new €25 million BioReliance(R) testing facility at its global headquarters in Darmstadt, Germany. The facility expands access to commercial drug substance and drug product release testing as well as stability testing for biopharmaceutical companies developing and commercializing therapies in Europe.

The 2,000-square-meter facility is designed to help customers meet European requirements for in-region drug substance and drug product release testing and expands the company's ability to support customers from drug development through commercialization.

The site will also offer Good Manufacturing Practice (GMP)-compliant stability studies for monoclona...